MedDataX Logo

To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

NCT ID: NCT00946725

Last Updated: 2017-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-11-30

Study Completion Date

2000-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To demonstrate the relative bioavailability of atenolol tablets, 100 mg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

NCT02259790

Healthy
COMPLETED PHASE1

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions

NCT00870571

Healthy
COMPLETED PHASE1

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions

NCT00870142

Healthy
COMPLETED PHASE1

A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions

NCT00865891

Healthy
COMPLETED PHASE1

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers

NCT01648231

Hypertension
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angina Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

Group Type EXPERIMENTAL

Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

Intervention Type DRUG

2

Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Group Type ACTIVE_COMPARATOR

Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)

Intervention Type DRUG

Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sandoz

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sandoz Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronald Goldwater, M.D.

Role: PRINCIPAL_INVESTIGATOR

PharmaKinetics Laboratories Inc.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11627

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions
NCT00865215 COMPLETED PHASE1
Amlodipine 10 mg Tablets Under Fasting Conditions
NCT00841542 COMPLETED PHASE1
A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions
NCT00864162 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions
NCT00946621 COMPLETED PHASE1
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
NCT05418348 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability of Diclofenac Sodium 50 mg Enteric-Coated Tablets Under Non-Fasting Conditions
NCT00914160 COMPLETED PHASE1
A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions
NCT00864617 COMPLETED PHASE1
Amlodipine-Benazepril 10mg-20mg Capsules in Healthy Subjects Under Fasting Conditions
NCT00834977 COMPLETED PHASE1
Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions
NCT00884442 COMPLETED PHASE1
Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg
NCT00649519 COMPLETED PHASE1
Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers
NCT02261064 COMPLETED PHASE1
Fed Study of Metoprolol Tartrate Tablets 25 mg and Lopressor® 50 mg
NCT00648271 COMPLETED PHASE1
Bioavailability Study of Propranolol Under Fasting Conditions
NCT00653120 COMPLETED PHASE2
Fed Study of Metoprolol Tartrate Tablets 100 mg and Lopressor® 100 mg
NCT00649116 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions
NCT00946465 COMPLETED PHASE1
A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study
NCT01822639 COMPLETED PHASE1
Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg
NCT00649818 COMPLETED PHASE1
Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Fasting Conditions
NCT01155895 COMPLETED PHASE1
A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions
NCT00864448 COMPLETED PHASE1
To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets
NCT00946608 COMPLETED PHASE1
Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects
NCT04411875 COMPLETED PHASE1
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition
NCT02292069 COMPLETED PHASE1
Amlodipine 10 mg Tablets Under Fed Conditions
NCT00841815 COMPLETED PHASE1
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
NCT03657550 COMPLETED PHASE1
Relative Bioavailability Study
NCT02159313 COMPLETED PHASE1